TY - JOUR
T1 - De Novo Heterozygous POLR2A Variants Cause a Neurodevelopmental Syndrome with Profound Infantile-Onset Hypotonia
AU - Haijes, Hanneke A.
AU - Koster, Maria J.E.
AU - Rehmann, Holger
AU - Li, Dong
AU - Hakonarson, H.
AU - Cappuccio, Gerarda
AU - Hancarova, Miroslava
AU - Lehalle, Daphne
AU - Reardon, Willie
AU - Schaefer, G. Bradley
AU - Lehman, Anna
AU - van de Laar, Ingrid M.B.H.
AU - Tesselaar, Coranne D.
AU - Turner, Clesson
AU - Goldenberg, A.
AU - Patrier, Sophie
AU - Thevenon, Julien
AU - Pinelli, Michele
AU - Brunetti-Pierri, Nicola
AU - Prchalová, Darina
AU - Havlovicová, Markéta
AU - Vlckova, Markéta
AU - Sedláček, Zdeněk
AU - Lopez, E.
AU - Ragoussis, Vassilis
AU - Pagnamenta, Alistair T.
AU - Kini, Usha
AU - Vos, Harmjan R.
AU - van Es, Robert M.
AU - van Schaik, Richard F.M.A.
AU - van Essen, Ton A.J.
AU - Kibaek, M.
AU - Taylor, Jenny C.
AU - Sullivan, Jennifer
AU - Shashi, Vandana
AU - Petrovski, S.
AU - Fagerberg, Christina
AU - Martin, Donna M.
AU - van Gassen, Koen L.I.
AU - Pfundt, R.
AU - Falk, Marni J.
AU - McCormick, Elizabeth M.
AU - Timmers, H. T.Marc
AU - van Hasselt, Peter M.
N1 - Funding Information:
We thank all included individuals and their families for their cooperation. We thank Ton A.J. van Essen, who unfortunately passed away during the completion of this manuscript. We are indebted to Craig Kaplan for providing yeast strains, plasmids, and insightful discussions. The human RPB1 cDNA was kindly provided by P. Cook. The study was supported by the following: grant 17-29423A from the Czech Ministry of Health for individuals with the p.Pro371Leu and p.Met769Thr variants; grant R6-388/WT100127 from the Oxford NIHR (National Institute for Health Research) Biomedical Research Centre and the Health Innovation Challenge Fund (a parallel funding partnership between the Wellcome Trust and the Department of Health) for the individual with the p.Gln735 ∗ variant; funding from the Duke Genome Sequencing Clinic , supported by the Duke University Health System , for the individual with the p.Ile848Thr variant; grant GSP15001 from the Telethon Foundation Telethon Undiagnosed Diseases Program for the individual with the p.Tyr1109His variant; and funding from Mining for Miracles ( BC Children’s Hospital Foundation ) and Genome British Columbia through the CAUSES (Clinical Assessment of the Utility of Sequencing as a Service) study for the individual with the p.Lys1125del variant. The investigators include Shelin Adam, Christèle du Souich, Alison M. Elliott, Anna Lehman, Jill Mwenifumbo, Tanya N. Nelson, Clara van Karnebeek, and Jan M. Friedman, and bioinformatics support was provided by the lab of Wyeth Wasserman. The work of H.T.M.T. is supported by the SFB850 and SFB992 programs of the Deutsche Forschungsgesellschaft (DFG). The mass spectrometry analysis was supported by the “Proteins at Work” program of the Netherlands Organization for Scientific Research (NWO, 184.032.201 ). The work of H.A. Haijes is supported by the personal Alexandre Suerman Stipend of the University Medical Centre Utrecht .
Funding Information:
We thank all included individuals and their families for their cooperation. We thank Ton A.J. van Essen, who unfortunately passed away during the completion of this manuscript. We are indebted to Craig Kaplan for providing yeast strains, plasmids, and insightful discussions. The human RPB1 cDNA was kindly provided by P. Cook. The study was supported by the following: grant 17-29423A from the Czech Ministry of Health for individuals with the p.Pro371Leu and p.Met769Thr variants; grant R6-388/WT100127 from the Oxford NIHR (National Institute for Health Research) Biomedical Research Centre and the Health Innovation Challenge Fund (a parallel funding partnership between the Wellcome Trust and the Department of Health) for the individual with the p.Gln735∗ variant; funding from the Duke Genome Sequencing Clinic, supported by the Duke University Health System, for the individual with the p.Ile848Thr variant; grant GSP15001 from the Telethon Foundation Telethon Undiagnosed Diseases Program for the individual with the p.Tyr1109His variant; and funding from Mining for Miracles (BC Children's Hospital Foundation) and Genome British Columbia through the CAUSES (Clinical Assessment of the Utility of Sequencing as a Service) study for the individual with the p.Lys1125del variant. The investigators include Shelin Adam, Christèle du Souich, Alison M. Elliott, Anna Lehman, Jill Mwenifumbo, Tanya N. Nelson, Clara van Karnebeek, and Jan M. Friedman, and bioinformatics support was provided by the lab of Wyeth Wasserman. The work of H.T.M.T. is supported by the SFB850 and SFB992 programs of the Deutsche Forschungsgesellschaft (DFG). The mass spectrometry analysis was supported by the “Proteins at Work” program of the Netherlands Organization for Scientific Research (NWO, 184.032.201). The work of H.A. Haijes is supported by the personal Alexandre Suerman Stipend of the University Medical Centre Utrecht.
Publisher Copyright:
© 2019
PY - 2019/8/1
Y1 - 2019/8/1
N2 - The RNA polymerase II complex (pol II) is responsible for transcription of all ∼21,000 human protein-encoding genes. Here, we describe sixteen individuals harboring de novo heterozygous variants in POLR2A, encoding RPB1, the largest subunit of pol II. An iterative approach combining structural evaluation and mass spectrometry analyses, the use of S. cerevisiae as a model system, and the assessment of cell viability in HeLa cells allowed us to classify eleven variants as probably disease-causing and four variants as possibly disease-causing. The significance of one variant remains unresolved. By quantification of phenotypic severity, we could distinguish mild and severe phenotypic consequences of the disease-causing variants. Missense variants expected to exert only mild structural effects led to a malfunctioning pol II enzyme, thereby inducing a dominant-negative effect on gene transcription. Intriguingly, individuals carrying these variants presented with a severe phenotype dominated by profound infantile-onset hypotonia and developmental delay. Conversely, individuals carrying variants expected to result in complete loss of function, thus reduced levels of functional pol II from the normal allele, exhibited the mildest phenotypes. We conclude that subtle variants that are central in functionally important domains of POLR2A cause a neurodevelopmental syndrome characterized by profound infantile-onset hypotonia and developmental delay through a dominant-negative effect on pol-II-mediated transcription of DNA.
AB - The RNA polymerase II complex (pol II) is responsible for transcription of all ∼21,000 human protein-encoding genes. Here, we describe sixteen individuals harboring de novo heterozygous variants in POLR2A, encoding RPB1, the largest subunit of pol II. An iterative approach combining structural evaluation and mass spectrometry analyses, the use of S. cerevisiae as a model system, and the assessment of cell viability in HeLa cells allowed us to classify eleven variants as probably disease-causing and four variants as possibly disease-causing. The significance of one variant remains unresolved. By quantification of phenotypic severity, we could distinguish mild and severe phenotypic consequences of the disease-causing variants. Missense variants expected to exert only mild structural effects led to a malfunctioning pol II enzyme, thereby inducing a dominant-negative effect on gene transcription. Intriguingly, individuals carrying these variants presented with a severe phenotype dominated by profound infantile-onset hypotonia and developmental delay. Conversely, individuals carrying variants expected to result in complete loss of function, thus reduced levels of functional pol II from the normal allele, exhibited the mildest phenotypes. We conclude that subtle variants that are central in functionally important domains of POLR2A cause a neurodevelopmental syndrome characterized by profound infantile-onset hypotonia and developmental delay through a dominant-negative effect on pol-II-mediated transcription of DNA.
KW - de novo variants
KW - desert regions
KW - desert Z score
KW - dominant-negative effect
KW - haplo-insufficiency
KW - infantile-onset hypotonia
KW - neurodevelopmental syndrome
KW - POLR2A
KW - RNA polymerase II complex
KW - RPB1
UR - http://www.scopus.com/inward/record.url?scp=85069833683&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2019.06.016
DO - 10.1016/j.ajhg.2019.06.016
M3 - Article
C2 - 31353023
AN - SCOPUS:85069833683
SN - 0002-9297
VL - 105
SP - 283
EP - 301
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 2
ER -